Navigation Links
Study Seeks Volunteers to Measure Safety of Treatment 'Boost' for Patients with Oropharyngeal Cancer
Date:7/23/2010

GREAT NECK, N.Y., July 23 /PRNewswire-USNewswire/ -- The North Shore-LIJ Health System Department of Radiation Medicine announced today it is seeking patients with cancer of the oropharynx (back of the mouth) to participate in a Phase I clinical trial.

Subjects must be newly diagnosed and not have undergone any previous treatment. Further, their cancer must be unassociated with the human papilloma virus (HPV-negative), or, if it is HPV-positive, they must be current or former pack-a-day smokers for at least 10 years.

Patients with HPV-negative oropharyngeal cancer are not cured as frequently by standard radiation therapy (IMRT) as are patients with the HPV-positive type, according to David Schwartz, MD, vice chair of radiation medicine at the North Shore-LIJ Health System and the study's principal investigator. The hypothesis of the study is that standard radiation therapy followed by a "boost" of image-guided stereotactic radiosurgery (SRS) will achieve a better cure rate for these two groups of patients.

Patients who volunteer to participate in the study are first screened to determine whether they are eligible, after which they provide their informed consent. Treatment can then begin--six weeks of standard radiation, possibly in combination with chemotherapy, depending on the stage of the cancer. Research nurse Sara Parise, RN, BSN, coordinates the patients' treatment.

And now on to the "boost" of SRS, which is what the study is all about. A Phase I trial establishes the safety of a treatment, and so the first group of patients receives a moderate dose of SRS, only 8Gy (Gy stands for gray, a unit of energy absorbed from ionizing radiation). This is a rigorous treatment, comparable to standard doses. All Phase I trials begin with a dose of the experimental treatment that is believed to be safe, followed by very careful monitoring of the patients' reactions. If the dose of 8Gy6 is well tolerated, the next group of patients will get a dose 2Gy higher, and again the side effects will be carefully monitored. The maximum dose will be 18Gy.

"This trial is one of the very first attempts to increase cure rates for the large number of patients with HPV-unassociated oropharyngeal cancer," Dr. Schwartz stated. "SRS is a safe, highly sophisticated technique that has generated much interest for its ability to overcome resistance of tumors to radiation. We are pleased that the North Shore-LIJ Health System has the technology and the expertise to offer this trial before any other center in the metropolitan area or anywhere in the country. Our hope is that it serves as a stepping stone for expanded use of SRS as part of standard treatment for people who face this illness."

To see if you are eligible to participate in the study or to find out more, call Ms. Parise at 718-470-7190, extension 66773.

This news release was issued on behalf of Newswise(TM).  For more information, visit http://www.newswise.com.


'/>"/>
SOURCE North Shore-Long Island Jewish Health System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
2. Lost and Found: L2FU Recovers 100% of Clinical Trial Patients for Recent Pivotal Study
3. AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides
4. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
5. Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
6. Worlds Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients
7. Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology
8. 12-Month Study Reports 90% Success Rate for AMS MiniArc Single-Incision Sling
9. New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)
10. Dune Medical Devices Announces Positive Interim Results From EU MarginProbe™ Study Presented at German Breast Cancer Society Meeting
11. Drug Study Shows Improvement in Major Orthopedic Surgery Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
Breaking Medicine News(10 mins):